Drug Type Small molecule drug |
Synonyms MK 8876 |
Target |
Action inhibitors |
Mechanism NS5B polymerase inhibitors(Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC32H24F2N4O5S |
InChIKeyGOHCXBUFLQKEIO-UHFFFAOYSA-N |
CAS Registry1426960-33-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatitis C, Chronic | Phase 1 | - | 02 Oct 2013 | |
Hepatitis C | Phase 1 | Germany | - | |
Hepatitis C | Phase 1 | Moldova | - |
Phase 1 | 9 | (Panel A: HCV GT3 MK-8876 150 mg) | wihzwmtojt(xyvhtnobfq) = avkfnnxpxj hhmbdnccnq (jaaahnbsxg, 0.12) View more | - | 04 Feb 2016 | ||
(Panel B: HCV GT3 MK-8876 800 mg) | wihzwmtojt(xyvhtnobfq) = foxgyvgknj hhmbdnccnq (jaaahnbsxg, 0.5) View more |